# Official Website: Atavistik Bio

**Type:** source
**Status:** Useful
**Confidence:** Medium
**Source Type:** Official Website
**URL:** https://atavistikbio.com
**Publisher:** Atavistik Bio
**Accessed:** 2026-06-19
**Updated:** 2026-06-19

## Summary

Atavistik Bio's official website describes a clinical-stage biotechnology company developing selective allosteric small-molecule therapeutics. The site positions the company's approach as enabling modulation of disease-causing proteins through non-active-site regulatory pockets, with pipeline programs in hereditary hemorrhagic telangiectasia (HHT), myeloproliferative neoplasms (MPNs), and additional discovery-stage assets.

## Useful Claims

- Atavistik Bio is a clinical-stage biotech developing novel allosteric therapeutics with potential for transformative treatment in serious diseases.
- Lead asset ATV-1601 is described as an oral, allosteric AKT1-selective inhibitor advancing for hereditary hemorrhagic telangiectasia (HHT).
- A JAK2 V617F mutant-selective inhibitor program is listed for myeloproliferative neoplasms (MPNs).
- Recent company news on the site reports a $120M Series B (December 2025), a $40M Series B extension (March 2026, bringing total round proceeds to $160M), and U.S. FDA clearance of an IND plus Fast Track designation for ATV-1601 in HHT (June 2026).
- The company invites candidates to join an "experienced and innovative team" through a careers page.

## Reliability Notes

This is an official company source. It is useful for pipeline positioning, financing announcements, and regulatory milestones, but clinical efficacy, competitive differentiation, and platform breadth should be cross-checked with SEC filings (if/when public), peer-reviewed publications, clinical trial registries, and independent biotech reporting. Pipeline emphasis on HHT in 2026 site copy may reflect program reprioritization relative to earlier public descriptions focused on AKT1 E17K solid tumors.

## Related Pages

- [Atavistik Bio](atavistik-bio.md)

## See Also

- [AMPS platform publication announcement (GlobeNewswire, 2023)](https://www.globenewswire.com/news-release/2023/03/13/2625643/0/en/Atavistik-Bio-Announces-Publication-in-Science-by-Co-Founder-Jared-Rutter-Describing-Foundational-Technology-for-its-Atavistik-Metabolite-Protein-Screening-AMPS-Platform.html) — founding platform science from co-founder Jared Rutter's lab